Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors

Approval Marks Neogene’s Transition to a Clinical-Stage Company NT-125 is a unique, multi-specific TCR therapy targeting neoantigens specific to each individual cancer patient SANTA MONICA, Calif., and AMSTERDAM, May 10, 2022 – Neogene Therapeutics, Inc., a global biotechnology company focused on discovering, developing, and manufacturing novel, transformative TCR therapies targeting neoantigens in solid cancers, today […]

Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer

Portfolio of TCRs developed in the laboratory of immunotherapy pioneer Steven Rosenberg, M.D., Ph.D. at the National Cancer Institute, combined with Neogene’s proprietary TCR isolation platform, provides expanded opportunities to target multiple neoantigens in individual patients Neogene plans to evaluate both autologous and allogeneic T cell therapies targeting neoantigens in a broad spectrum of solid […]

Neogene Therapeutics Appoints Raphaël Rousseau, M.D., Ph.D., as Chief Medical Officer

Dr. Rousseau brings extensive scientific expertise and industry experience in the development of T cell therapies and will lead Neogene’s efforts to advance next-generation, fully individualized T cell therapies into the clinic SANTA MONICA, Calif., and AMSTERDAM, December 16, 2021 – Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully […]

Neogene Therapeutics Appoints Han Lee, Ph.D., MBA, as Chief Financial Officer

Dr. Lee will support Neogene’s continued growth as it advances a new class of fully individualized TCR therapies for solid tumors to the clinic SANTA MONICA, Calif., and AMSTERDAM, September 14, 2021 – Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully individualized T cell receptor (TCR) therapies to treat […]

Neogene Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA as Chief Operating Officer

Most recently served as senior vice president, U.S. Oncology, at Bristol Myers Squibb and brings an industry-leading track record in oncology and general management Will lead expansion of Neogene with U.S. headquarters in Santa Monica, Calif., as the company’s location for its cell therapy development group spear-heading the clinical translation of novel neo-antigen T cell […]

Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine

Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine NEW YORK and AMSTERDAM, January 26, 2021 – Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company’s […]

Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies SOUTH SAN FRANCISCO, Calif.  and AMSTERDAM, The Netherlands – October 13, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and […]

Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors

Four Additional Board Members Appointed to Complement Founding Expertise NEW YORK and AMSTERDAM, October 6, 2020 – Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Franz B. Humer, Ph.D., as Executive Chairman of the Board of […]

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies

Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform identifies specific T cell receptor (TCR) genes from routine tumor samples using state-of-the-art synthetic biology tools Co-founded by renowned T cell engineering expert Ton Schumacher, Ph.D. and […]